Sign in
CompletedPhase 4

Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication

Key facts

Who runs it
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Where
Bangladesh1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
80 people enrolled
Started
15 Apr 2026
Ended
14 Sept 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • vonoprazan-based triple therapy (VAL regimen)
  • Esomeprazole-based triple therapy (EAL regimen)
Record updated
26 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Dyspeptic patients with positive for both rapid urease test and stool antigen test
  • Patients giving written informed consent

Who cannot take part

  • Treatment with a proton pump inhibitor, H2-receptor antagonist within the last 2 weeks, prior to the study
  • Treatment with antibiotics or bismuth preparation within 4 weeks prior to the study
  • Previous H. pylori eradication therapy
  • Patients with regular intake of NSAIDs or steroids
  • Surgery that might affect gastric acid secretion e.g., upper GI resection or vagotomy
  • Chronic alcohol abuse, chronic illegal drug use, or drug addiction within the past 12 months
  • Gastric or duodenal ulcer with current or recent bleeding on endoscopy
  • Significant upper or lower gastrointestinal bleeding within 4 weeks
  • Known case of malignancy, including MALToma
  • Advanced co-morbidities (e.g., CLD, CKD, cardio-respiratory failure, known thyroid disease)
  • History of hypersensitivity to vonoprazan, PPIs, amoxicillin, and/or levofloxacin
  • Subjects with abnormal laboratory test at the start of the screening period:
  • creatinine > 2 mg/dl SGPT > 2 x Upper limit of normal
  • Pregnant, lactating woman or intend to become pregnant within the study period
  • On colchicine

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter pylori infection in adults with dyspepsia.

Read full original descriptionShow less

The main questions it aims to answer are whether vonoprazan-based triple therapy achieves a higher eradication rate of H. pylori, whether it provides greater improvement in dyspeptic symptoms, and what adverse effects are associated with each regimen.

Researchers will compare the two treatment regimens to determine which is more effective for H. pylori eradication.

Participants with confirmed H. pylori infection will be randomly assigned to receive either vonoprazan-based or esomeprazole-based triple therapy for 14 days.

Four weeks after completion of therapy, participants will undergo repeat stool antigen testing to assess eradication.

Drug compliance, adverse effects, and dyspeptic symptom scores will be recorded during follow-up.

Participants with endoscopic mucosal lesions at baseline will undergo follow-up endoscopy for reassessment.

The 2 groups in the trial

  • Vonoprazan-based triple therapy (VAL)Treatment being tested

    Participants in this arms will receive vonoprazan based levofloxacin containing triple therapy for 14 days

    Treatment: vonoprazan-based triple therapy (VAL regimen)

  • Esomeprazole-based triple therapy (EAL)Existing treatment, for comparison

    Participants in this arms will receive esomeprazole based levofloxacin containing triple therapy for 14 days

    Treatment: Esomeprazole-based triple therapy (EAL regimen)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison Between Vonoprazan-Based Triple Therapy and Esomeprazole-Based Triple Therapy for Eradication of Helicobacter Pylori Infection: An Open-Label Randomized Controlled Trial
Record updated
26 October 2026